This biomarker is also known as:
- tax-responsive element-binding protein 5,
- X-box binding protein 1,
- Tax-responsive element-binding protein 5,
- X-box-binding protein 1,
View in BioMuta
XBP1 is a transcription factor involved in hepatocyte growth, differentiation of plasma cells, immunoglobulin secretion, and the unfolded protein response (UPR). XBP1 regulates MHC class II genes by binding to a promoter element referred to as an X box. XBP1 also plays a role in activating unfolded protein response (UPR) target genes via direct binding to the UPR element (UPRE) during endoplasmic reticulum stress. There is an XBP1 pseudogene on chromosome 5.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
XBP1 is also an estrogen-regulated gene and strongly correlates with estrogen receptor alpha (ERÎ±) expression in breast cancers.
XBP1 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.